Methylphenidate for Ptsd and Stroke Veterans
Model scores of the 29,894 trials active now.
Model score 15% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase and sponsor type, started 2008–2016) ended terminated 18% of the time (243 trials).
Finished trial that started in 2015 or later: the model never saw it during training.
How it ended
Completed on 2025-05-05, after 2022-01-14 start.
The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.
Termination over time, as the model saw it at the start
Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-05-05. The rest of the way to 100% is still running.
From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.
What moved the score
-
Wording of the registration (title, summary, criteria) (raises risk) · Wording
Phrases that raised it: priormonthsscoreplacebotype
Phrases that lowered it: participantparticipantsclinical trialsconditionsformulation -
Accepts healthy volunteers: No (raises risk) · Who can join
-
Phase: 1/2 (raises risk) · Design
-
Minimum age: 40 (lowers risk) · Who can join
-
Drug's FAERS reports marked serious: 49.1% (lowers risk) · Drug's FDA history
-
Sponsor's past trials: 704 (raises risk) · Sponsor's track record
-
Sponsor's past termination rate: 6.5% (lowers risk) · Sponsor's track record
-
Disease area, neurology: Yes (raises risk) · Disease area
-
Has a data monitoring committee: Yes (raises risk) · Design
-
Design: parallel (raises risk) · Design
-
Blinding: quadruple (lowers risk) · Design
-
Drug's FAERS reports with a death: 3.7% (lowers risk) · Drug's FDA history
-
Trials the sponsor started in the prior 2 years: 173 (lowers risk) · Sponsor's track record
-
Disease area, cancer: No (lowers risk) · Disease area
-
Primary purpose: treatment (raises risk) · Design
-
Disease area, psychiatry: Yes (raises risk) · Disease area
-
Number of arms: 2 (raises risk) · Design
-
Disease area, cardiovascular: Yes (raises risk) · Disease area
-
Collaborators: 0 (raises risk) · Design
Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.
The trial
Design
- Phase
- 1/2 (typical: 2)
- Number of arms
- 2
- Allocation
- randomized
- Design
- parallel
- Primary purpose
- treatment
- Blinding
- quadruple (typical: none)
- Has a data monitoring committee
- Yes (typical: 56% yes)
- Responsible party
- sponsor
- Collaborators
- 0
- Keywords listed
- 2 (typical: 1)
Who can join
- Minimum age
- 40 (typical: 18)
- Maximum age
- 75 (typical: 71)
- Sex
- all
- Accepts healthy volunteers
- No (typical: 9% yes)
Sponsor's track record
- Sponsor type
- government (typical: academic or other)
- Sponsor's past trials
- 704 (typical: 32)
- Sponsor's past termination rate
- 6.5% (typical: 9.9%)
- Trials the sponsor started in the prior 2 years
- 173 (typical: 19)
Drug's FDA history
- Drugs with FDA adverse-event history
- 1
- Drug has FAERS history
- Yes (typical: 64% yes)
- Drug's FAERS reports before start
- 60202 (typical: 2148)
- Drug's FAERS reports in the prior 12 months
- 3241 (typical: 412.5)
- Drug's FAERS reports marked serious
- 49.1% (typical: 85.6%)
- Drug's FAERS reports with a death
- 3.7% (typical: 15.9%)
Disease area and drugs
- Disease areas
- cardiovascular, neurology, psychiatry
- Drugs matched to FDA substances
- methylphenidate
Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.
Similar finished trials
- Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy NCT02727998 · started 2015 · scored riskier than 11% of active trials terminated
- MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD NCT05979844 · started 2023 · scored riskier than 65% of active trials completed
- A mGlu2/3 Agonist in the Treatment of PTSD NCT02234687 · started 2014 · scored riskier than 35% of active trials terminated
- Cognitive REmediation After Trauma Exposure Trial = CREATE Trial NCT01416948 · started 2011 · scored riskier than 53% of active trials terminated
- Phase II Study of BNC210 in PTSD NCT02933606 · started 2016 · scored riskier than 70% of active trials completed
Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.